Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

<p>Oryzon presented more granular data from Phase I/IIa in acute leukaemia at the American Society of Hematology (ASH) meeting after the positive headline results had been announced earlier. ORY-1001&rsquo;s further development is now in Roche&rsquo;s hands, which also initiated a Phase I trial in a new indication small cell lung cancer (SCLC). Recently Oryzon released preclinical data supporting ORY-2001&rsquo;s potential in multiple sclerosis (MS), which we now include in our valuation. All these developments led to an increase in our Oryzon&rsquo;s valuation to &euro;250m.</p>

Oryzon presented more granular data from Phase I/IIa in acute leukaemia at the American Society of Hematology (ASH) meeting after the positive headline results had been announced earlier. ORY-1001&rsquo;s further development is now in Roche&rsquo;s hands, which also initiated a Phase I trial in a new indication small cell lung cancer (SCLC). Recently Oryzon released preclinical data supporting ORY-2001&rsquo;s potential in multiple sclerosis (MS), which we now include in our valuation. All these developments led to an increase in our Oryzon&rsquo;s valuation to &euro;250m.

Spain

Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Oryzon Genomics (ORY SM)

Expanding clinical R&amp;D pipeline

Oryzon presented more granular data from Phase I/IIa in acute leukaemia at the American Society of Hematology (ASH) meeting after the positive...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Expanding clinical R&amp;amp;D pipeline

Oryzon presented more granular data from Phase I/IIa in acute leukaemia at the American Society of Hematology (ASH) meeting after the positive...

Edison Investment Research

Expanding clinical R&D pipeline